Ranked in Legal 500 (Legalease) 2017 as a "next generation lawyer" for pharmaceuticals, biotechnology and life sciences, Jonathan is an IP litigator in the London disputes practice of Herbert Smith Freehills. From Jonathan's doctoral studies, he also understands a broad spectrum of scientific disciplines including chemistry, biochemistry, genetics and molecular biology. Jonathan uses his strong scientific background to work closely with global R&D based pharmaceutical companies to prepare and implement multi-jurisdictional strategies by collaborating with lawyers across Europe and beyond. Jonathan's core practice is to assist these companies meet their commercial aims in relation to their blockbuster drugs (both small molecule and biological medicines). From Jonathan's experiences handling such matters, he has developed a deep understanding of the pharmaceutical and life sciences sectors with particular specialism in issues concerning SPCs and market access, and he has coordinated patent litigation in most European countries. Jonathan also has extensive experience in both advising and acting in intellectual property disputes in the UK, including on issues of employee inventor compensation. Jonathan is currently advising, or has recently advised, clients before all relevant forums in the UK: UK-IPO, High Court, Court of Appeal, Supreme Court and Courts of Justice of the European Union. In doing so, Jonathan has acted for major national and international clients in both enforcing and challenging intellectual property rights. Jonathan is also a solicitor advocate with rights of audience in all civil proceedings in the UK.